Antibiotic resistance of Helicobacter pylori

Journal of Applied Microbiology Symposium Supplement

Volumn 90, Issue 30, 2001, Pages

  Kusters, J G ^a,b   Kuipers, E J ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BISMUTH; CIPROFLOXACIN; CLARITHROMYCIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RIFAMPICIN; STOMACH SECRETION INHIBITOR; STREPTOMYCIN; TETRACYCLINE DERIVATIVE; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; CONFERENCE PAPER; DISEASE ASSOCIATION; ERADICATION THERAPY; HELICOBACTER PYLORI; HEREDITY; PEPTIC ULCER; PERSONALITY; STRESS; TREATMENT OUTCOME;

BACILLI; BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI;

EID: 0034976824     PISSN: 02674440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (108)

1. Recombination and clonal groupings within Helicobacter pylori from different geographical regions
2. Successful Helicobacter pylori eradication: A systemic effect of antibiotics?
3. Discrepancies between E-test and agar dilution methods for testing metronidazole susceptibility of Helicobacter pylori
4. In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates of Helicobacter pylori
5. The MACH 2 Study: Value of inhibiting gastric acid secretion in eradication of Helicobacter pylori with a one week triple therapy protocol
6. Helicobacter pylori in peptic ulcer disease: Report of an NIH consensus conference
7. Ueber die schlauchfoermigen drusen des magendarmkanals und die beziehungen ihres epithels zu dem oberflachenepithel der sleimhaut
8. Hypothesis: The changing relationships of Helicobacter pylori and humans: Implications for health and disease
9. In a world of black and white, Helicobacter pylori is gray
10. Helicobacter pylori: A true carcinogen?
11. Proposed mechanism for metronidazole resistance in Helicobacter pylori
12. Isolation of a genetic locus associated with metronidazole resistance in Helicobacter pylori
13. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori
14. NIH consensus panel urges antimicrobials for ulcer patients, skeptics concur with caveats
15. Did the inheritance of a pathogenicity island modify the virulence of Helicobacter pylori?
16. Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori
17. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands
18. Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents
19. Insertion of mini-IS605 and deletion of adjacent sequences in the nitroreductase (rdxA) gene cause metronidazole resistance in Helicobacter pylori NCTC11637
20. Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori
21. Eradication of Helicobacter pylori: Why does it fail?
22. Spirochetes in the gastric glands of Macacus rhesus and humans without definite history of related disease
23. Different penicillin-binding protein profiles in amoxicillin-resistant Helicobacter pylori
24. Sensitivity of amoxicillin-resistant Helicobacter pylori to other penicillins
25. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: A meta-analytical approach
26. Amoxycillin tolerance in Helicobacter pylori
27. Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of Helicobacter pylori infection
28. Nitroimidazole drugs - Action and resistance mechanisms. I. Mechanisms of action
29. Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin
30. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori
31. Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes
32. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase
33. Antibiotic resistance in Helicobacter pylori: Implications for therapy
34. Factors influencing the eradication of Helicobacter pylori with triple therapy
35. Variability with omeprazole-amoxicillin combinations for treatment of Helicobacter pylori infection
36. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents
37. Aflagellated mutants of Helicobacter pylori generated by genetic transformation of naturally competent strains using transposon shuttle mutagenesis
38. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones
39. Characterisation of a Helicobacter pylori phage (HP1)
40. Metabolic activities of metronidazole-sensitive and -resistant strains of Helicobacter pylori: Repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance
41. Helicobacter pylori eradication therapy in The Netherlands
42. A systematic review of Helicobacter pylori eradication therapy - The impact of antimicrobial resistance on eradication rates
43. The activity of metronidazole against facultatively anaerobic bacteria
44. The role of the rdxA gene in the evolution of metronidazole resistance in Helicobacter pylori
45. The mode of action of metronidazole in Helicobacter pylori: Futile cycling or reduction?
46. Flavodoxin-dependent pyruvate oxidation, acetate production and metronidazole reduction by Helicobacter pylori
47. Evidence for a conjugation-like mechanism of DNA transfer in Helicobacter pylori
48. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis
49. Helicobacter pylori in gastrooesophageal reflux disease: Causal agent, independent or protective factor?
50. Metronidazole uptake by sensitive and resistant isolates of Helicobacter pylori
51. The MACH 2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies
52. Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain
53. Horizontal genetic exchange, evolution, and spread of antibiotic resistance in bacteria
54. Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin
55. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis
56. Attempt to fulfil Koch's postulates for pyloric Campylobacter
57. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration
58. Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa
59. Antimicrobial resistance testing of Helicobacter pylori: A comparison of Etest and disk diffusion methods
60. Helicobacter pylori resistance to tetracycline
61. Metronidazole uptake in Helicobacter pylori
62. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori
63. Catalase and superoxide dismutase secreted from Helicobacter pylori
64. Natural competence for genetic transformation in Campylobacter pylori
65. Helicobacter pylori in peptic ulcer disease. NIH consensus development panel on Helicobacter pylori in peptic ulcer disease
66. Macrolide resistance in Helicobacter pylori: Rapid detection of point mutations and assays of macrolide binding to ribosomes
67. Eradication of Helicobacter pylori: An objective assessment of current therapies
68. The reductive metabolism of metronidazole and ronidazole by aerobic liver microsomes
69. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential
70. Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents
71. Histological aspects of Campylobacter pylori colonisation and infection of gastric and duodenal mucosa
72. Primary resistance to metronidazole and other antibiotics of Helicobacter pylori isolated from children in Poland
73. Reflux esophagitis: A complication of Helicobacter pylori eradication therapy?
74. Bacteriophages in Helicobacter (Campylobacter)
75. Electroporation of Helicobacter pylori
76. Transformation of Helicobacter pylori by electroporation
77. Redox potential and oxygen concentration as factors in the susceptibility of Helicobacter pylori to nitroheterocyclic drugs
78. Oxygen scavenging, NADH oxidase and metronidazole resistance in Helicobacter pylori
79. Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori
80. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori
81. A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia
82. Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region: First Asian Pacific working party on functional dyspepsia
83. Frequent association between alteration of the rdxA gene and metronidazole resistance in French and North African isolates of Helicobacter pylori
84. Transformation of H. pylori by plasmid
85. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations
86. Acid pH decreases OmpF and OmpC channel size in vivo
87. Genetic transformation in Helicobacter pylori
88. Treatment of Helicobacter pylori infection: A review of the world literature
89. Prevention of ulcer recurrence after eradication of Helicobacter pylori: A prospective long-term follow-up study
90. Review article: Nitroimidazole resistance in Helicobacter pylori
91. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: A meta-analysis
92. Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands
93. Rapid detection, by PCR and reverse hybridization, of mutations in the Helicobacter pylori 23S rRNA gene, associated with macrolide resistance
94. Secretion of intravenously administered antibiotics in gastric juice: Implications for management of Helicobacter pylori
95. Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains
96. Stable amoxicillin resistance in Helicobacter pylori
97. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori
98. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease
99. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease
100. Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori
101. Transformation of Helicobacter pylori by chromosomal metronidazole resistance and by a plasmid with a selectable chloramphenicol resistance marker
102. Unidentified curved bacilli on gastric epithelium in active chronic gastritis
103. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis
104. New options in Helicobacter pylori eradication: Efficacy, resistance and synergy
105. Clarithromycin resistance in Helicobacter pylori: Prevalence in untreated dyspeptic patients and stability in vitro
106. Recurrence of Helicobacter pylori infection after successful eradication: Nature and possible causes
107. NIH consensus on Helicobacter pylori in peptic ulcer disease